National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Trastuzumab deruxtecan (Enhertu®). HTA ID: 22050

Trastuzumab deruxtecan (Enhertu®) is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.


NCPE Assessment Process Complete
Rapid review commissioned 11/07/2022
Rapid review completed 27/07/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care.